Geriatric Assessment for Older Adults with Acute Myeloid Leukemia
This study is for adults aged 60 and older who have been newly diagnosed with Acute Myeloid Leukemia (AML), a type of blood cancer. It's testing if using a "geriatric assessment" (GA) to guide treatment choices can reduce side effects and improve how you feel, compared to standard care. The GA helps doctors understand your overall health, not just your age. Depending on your GA results (fit, vulnerable, or frail), you would receive specific treatment regimens. The main goal is to see how many people experience treatment failure within 3 months. This study is currently unclear on its recruitment status.
- Study design
- This is a Phase 2 randomized controlled trial involving 120 participants. It compares a geriatric assessment-guided treatment strategy to usual oncologist-directed care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at 3 months after treatment initiation to assess treatment failure rate.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Treatment failure rate at 3 months3 months after treatment initiation
Treatment failure is defined as the occurrence of any of the following within 3 months after treatment initiation: disease progression or relapse, death from any cause, treatment discontinuation for any reason except logistical reasons, absence of at least one agent in the initial treatment regimen for more than 30 days following the last day of the previous treatment cycle (temporary dose interruptions and cycle delays within the 30 day window are not considered treatment failure events), or initiation of an alternative treatment regimen or addition of an agent because of clinician documented concern for lack of efficacy or disease control.